Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Long-Term Deferred Tax (2016 - 2024)

ENDRA Life Sciences has reported Long-Term Deferred Tax over the past 4 years, most recently at $13.8 million for Q4 2021.

  • Quarterly Long-Term Deferred Tax rose 22.55% to $13.8 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Dec 2021, up 22.55% year-over-year, with the annual reading at $13.8 million for FY2021, 22.55% up from the prior year.
  • Long-Term Deferred Tax was $13.8 million for Q4 2021 at ENDRA Life Sciences, up from $11.3 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $13.8 million in Q4 2021 and troughed at $4.0 million in Q4 2017.
  • The 3-year median for Long-Term Deferred Tax is $11.3 million (2020), against an average of $9.7 million.
  • Year-over-year, Long-Term Deferred Tax rose 5.75% in 2017 and then grew 22.55% in 2021.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $4.0 million in 2017, then skyrocketed by 180.64% to $11.3 million in 2020, then increased by 22.55% to $13.8 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Long-Term Deferred Tax are $13.8 million (Q4 2021), $11.3 million (Q4 2020), and $4.0 million (Q4 2017).